Google backs $27M launch round for Holy Grail R&D work on two targets: a cancer vaccine and a universal flu jab
Vaccitech isn’t just going after one of the Holy Grails in biotech R&D. It’s taking aim at two of them.
A spinout from some leading vaccine experts at Oxford’s Jenner Institute, the startup has been following up on new research to go after both a universal flu vaccine as well as a cancer vaccine angling for a place in the bright spotlight now focused on immuno-oncology. And it now has a $27 million round to advance tests in humans.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.